Comparative Pharmacology
Head-to-head clinical analysis: ESLICARBAZEPINE ACETATE versus ZONEGRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESLICARBAZEPINE ACETATE versus ZONEGRAN.
ESLICARBAZEPINE ACETATE vs ZONEGRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes the inactive state of sodium channels, reducing high-frequency repetitive firing of neurons. It also modulates T-type calcium channels and enhances slow inactivation of sodium channels.
Anticonvulsant; blocks voltage-gated sodium and calcium channels, enhances GABA-mediated inhibition, and inhibits glutamate release.
400 mg orally once daily, titrated to a maintenance dose of 800-1200 mg once daily.
Initial: 100 mg orally once daily for 2 weeks, then may increase by 100 mg/day at 2-week intervals; usual maintenance: 200-400 mg/day divided once or twice daily; maximum: 600 mg/day.
None Documented
None Documented
Clinical Note
moderateEslicarbazepine acetate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateEslicarbazepine acetate + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateCyclophosphamide + Eslicarbazepine acetate
"The metabolism of Eslicarbazepine acetate can be decreased when combined with Cyclophosphamide."
Clinical Note
moderateTerminal half-life of eslicarbazepine is 13-20 hours (mean ~14 hours), supporting once-daily dosing.
Terminal elimination half-life is approximately 63 hours (range 50-70 hours) in adults. The long half-life allows for once- or twice-daily dosing. Steady state is reached after about 2 weeks of repeated dosing.
Renal: ~90% (as glucuronide conjugates and unchanged drug; ~30% as eslicarbazepine acetate, ~60% as eslicarbazepine). Fecal: <1%. Biliary: negligible.
Renal: approximately 62% of the dose as unchanged drug and metabolites (primarily glucuronide conjugates and N-acetylzonisamide). Fecal: approximately 16% (including metabolites). Biliary excretion is minimal. Total recovery in urine and feces accounts for ~80% of the dose.
Category C
Category C
Anticonvulsant
Anticonvulsant
Phenytoin + Eslicarbazepine acetate
"The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenytoin."